Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Pulse Biosciences' Accumulated Expenses rose 3616.85% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 3616.85%. This contributed to the annual value of $7.0 million for FY2024, which is 8424.23% up from last year.
  • Latest data reveals that Pulse Biosciences reported Accumulated Expenses of $5.2 million as of Q3 2025, which was up 3616.85% from $4.8 million recorded in Q2 2025.
  • Pulse Biosciences' 5-year Accumulated Expenses high stood at $7.0 million for Q4 2024, and its period low was $2.3 million during Q1 2024.
  • Over the past 5 years, Pulse Biosciences' median Accumulated Expenses value was $4.0 million (recorded in 2022), while the average stood at $4.1 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 17122.16% in 2021, then plummeted by 4021.44% in 2023.
  • Over the past 5 years, Pulse Biosciences' Accumulated Expenses (Quarter) stood at $3.8 million in 2021, then plummeted by 31.96% to $2.6 million in 2022, then soared by 46.97% to $3.8 million in 2023, then skyrocketed by 84.24% to $7.0 million in 2024, then decreased by 25.96% to $5.2 million in 2025.
  • Its Accumulated Expenses stands at $5.2 million for Q3 2025, versus $4.8 million for Q2 2025 and $4.0 million for Q1 2025.